TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

ETAS ID: TM769264

SUBMISSION TYPE: NEW ASSIGNMENT

NATURE OF CONVEYANCE: ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Pfizer Inc.		08/16/2022	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	Antares Pharma, Inc.	
Street Address:	100 Princeton South, Suite 300	
City:	Ewing	
State/Country:	NEW JERSEY	
Postal Code:	08628	
Entity Type:	Corporation: DELAWARE	

PROPERTY NUMBERS Total: 2

Property Type	Number	Word Mark
Serial Number:	88752697	NAXREDI
Serial Number:	88752698	NAXREDY

CORRESPONDENCE DATA

Fax Number: 6509385200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 650-988-8500

Email: trademarks@fenwick.com

Karen A. Webb. Fenwick & West LLP **Correspondent Name:**

Address Line 1: 801 California Street Address Line 2: Silicon Valley Center

Address Line 4: Mountain View, CALIFORNIA 94041

ATTORNEY DOCKET NUMBER:	38574-00101
NAME OF SUBMITTER:	Karen Webb
SIGNATURE:	/kaw/
DATE SIGNED:	11/21/2022

Total Attachments: 1

source=Pfizer Antares Confirmation of Trademark Assignment#page1.tif

TRADEMARK REEL: 007899 FRAME: 0211

900733459

CONFIRMATION OF TRADEMARK ASSIGNMENT

This Confirmation of Trademark Assignment ("Assignment") is entered into by and between Pfizer Inc., a Delaware corporation with a place of business at 235 East 42nd Street, New York, New York 10017 ("Assignor"), and Antares Pharma, Inc., a company incorporated under the laws of the State of Delaware and having its principal place of business at 100 Princeton South, Suite 300, Ewing, New Jersey 08628 ("Assignee"). Assignor and Assignee, jointly, referred to herein as the "Parties."

WHEREAS, Assignor is the owner of trademarks, NAXREDY, U.S. App. No. 88752698 and NAXREDI, U.S. App. No. 88752697, filing dates January 9, 2020 ("the Naxredy Marks").

WHEREAS, pursuant to a prior Second Amendment to the Development Agreement, ("Second Amendment") effective August 10, 2022 ("Effective Date"), by and among Assignor and Assignee, certain intellectual property rights, including without limitation all legal rights, title and interest in and to the Naxredy Marks, were assigned to Assignee.

NOW, THEREFORE, this confirms that in consideration of the promises and undertakings set forth in the Second Amendment, and other good and valuable consideration, the receipt of which is hereby acknowledged, Assignor assigned and transferred unto Assignee all legal rights, title and interest in and to the Naxredy Marks and all the legal rights, claims and privileges pertaining to the Naxredy Marks, including without limitation, the applications pertaining thereto, common law rights, together with the goodwill of the business associated with and symbolized by the Naxredy Marks, and that portion of the business which is ongoing and existing to which the Naxredy Marks pertain, and the right to sue and recover damages for past, present and future infringements thereof and to stand in the place of Assignor in all matters related thereto.

IN WITNESS WHEREOF, Assignor and Assignee have caused this Assignment to be made as of the Effective Date referenced above.

Pfizer Inc. — DocuSigned by:	Antares Pharma, Inc.
By: Lisa Skeens Name: Lisa Skeens	By: MALL SNYLEL
Title: VP GRA CMC and Hospital	Title: 51/19 & 61/1901 100/152
Date: August 16, 2022	Date:

TRADEMARK REEL: 007899 FRAME: 0212

RECORDED: 11/21/2022